CVS readies a set of outcomes-based contracts for its clients

While announcing its annual update of drugs (now around 36) to be excluded from its “Standard Control Formulary” in 2018, the industry-leading pharmacy benefit manager (PBM) is also hinting at another cost-control measure: outcomes-based contracting. Such programs have been occasionally entered […]

Read More

FDA schedules public meetings for DSCSA

FDA is following through on requirements, under the Drug Supply Chain Security Act (DSCSA), to hold public meetings on where it is going with the law, whose implementation started in 2015 and will continue (under current timetables) until 2023. A […]

Read More